BioCentury
ARTICLE | Company News

NeRRe debuts with L11.5 million

December 20, 2012 1:32 AM UTC

NeRRe Therapeutics Ltd. (Stevenage, U.K.) debuted on Wednesday to develop a pipeline of four clinical and preclinical neurokinin receptor antagonists from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), which has an undisclosed minority stake in the newco. NeRRe also raised L11.5 million ($18.6 million) from Novo A/S and Advent Venture Partners in a series A round. NeRRe said it will initially focus on advancing an undisclosed neurokinin 1 substance P ( TAC1; NK1) antagonist into Phase II testing, but the company declined to disclose details. ...